Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes

Immunotherapy, especially anti-PD-1, is becoming a pillar of modern muscle-invasive bladder cancer (MIBC) treatment. However, the objective response rates (ORR) are relatively low due to the lack of precise biomarkers to select patients. Herein, the molecular subtype, tumor mutation burden (TMB), an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hereditas
Main Authors: Chen, Zihao, Liu, Guojun, Liu, Guoqing, Bolkov, Mikhail A., Shinwari, Khyber, Tuzankina, Irina A., Chereshnev, Valery A., Wang, Zhifeng
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7778803/
https://ncbi.nlm.nih.gov/pubmed/33388091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41065-020-00165-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados